ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1433

A 48-week Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis

Ulf Müller-Ladner1, Karl Gaffney2, Deepak Jadon3, Marco Matucci-Cerinic4, Eugenio Chamizo Carmona5 and Janet Addison6, 1JLU Campus KK, Bad Nauheim, Germany, 2Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, 3Cambridge University, Cambridge, United Kingdom, 4University of Florence, Florence, Italy, 5Hospital de Mérida, Mérida, Spain, 6Biogen Idec Ltd, Maidenhead, United Kingdom

Meeting: ACR Convergence 2022

Keywords: Biologicals, Psoriatic arthritis, rheumatoid arthritis, spondyloarthritis, Tumor necrosis factor (TNF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Treatment Poster III

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: SB5, a biosimilar to reference adalimumab (ADL), received marketing authorisation in 2017 (EU) and 2019 (US) based on pre-clinical and clinical phase I and III studies demonstrating bioequivalence and comparable efficacy, safety and immunogenicity to ADL. The real-world study ‘PROPER’ is designed to provide insights into outcomes of the transition from ADL to SB5 outside the randomised, controlled, clinical trial setting.

Methods: Under an umbrella design, 1040 patients with immune-mediated inflammatory disease (rheumatoid arthritis [RA], axial spondyloarthritis [axSpA], psoriatic arthritis [PsA], Crohn’s disease [CD], and ulcerative colitis [UC]) were enrolled at centres in Belgium, Germany, Ireland, Italy, Spain and UK, and followed for 48 weeks post-transition to SB5 after at least 16 weeks’ routine treatment with ADL. This abstract presents results for the RA, axSpA and PsA cohorts.

The study aimed to evaluate candidate predictors of persistence on SB5; these variables included gender, medical history, age, duration of disease, disease score and concomitant therapy, all at time of SB5 initiation. Variables reported for at least 15% of each cohort, and having clinical relevance, were selected as candidate predictors, fitted into a univariate Cox regression model, and hazard ratios (HR) calculated for each variable. Persistence on SB5 i.e. time to SB5 discontinuation up to Week 48 post-transition was estimated using the Kaplan-Meier method.

Results: Of the 496 patients included in this analysis, 487 completed 48 weeks of study follow-up; 397 of those (81.5%) remained on SB5 throughout. Probability of persistence at Week 48 was 85.9%, 79.5% and 81.1% for RA, axSpA and PsA, respectively (Figure 1).

Table 1 shows the variables selected as candidate predictors, and the probability of each to predict persistence at Week 48. Being female was the only variable shown to be significantly associated with persistence: HR (95% CI) 3.53 (1.1, 11.7 [p=0.04]) and 2.38 (1.1, 5.1 [p=0.03]) in the RA and axSpA cohorts, respectively. Of the 3 variables with HR ≥1.5, or the reciprocal, the 95% CI crossed 1.0 and the association with persistence was not statistically significant (based on p-value): female gender (in the PsA cohort); history of vascular disorders (in the RA cohort); and receiving folic acid supplement (in the RA and PsA cohorts).

Conclusion: Over three quarters of all three rheumatology indication cohorts remained on SB5 by 48 weeks after transition from reference ADL. Of the candidate predictors of persistence, only female gender was found to have a significant association with increased risk for SB5 discontinuation in study subjects diagnosed with RA or axSpA. A limitation of this finding is the relatively low proportion of subjects discontinuing SB5 prior to Week 48, hence a low incidence of potential candidate predictors within the dataset; p-values should be interpreted with caution. These results suggest that, within the baseline categories explored, no evidence was found to mitigate against transition on grounds of baseline clinical characteristics in terms of anticipated persistence.

Supporting image 1

Table 1. Probability of candidate variable to predict persistence.

Supporting image 2

Figure 1. Probability of remaining on SB5


Disclosures: U. Müller-Ladner, Biogen; K. Gaffney, AbbVie, Eli Lilly, Novartis, UCB Pharma, Gilead; D. Jadon, AbbVie, Celgene, Eli Lilly, Gilead, Janssen, MSD, Novartis, Oxford University Press, Pfizer, Roche, Sandoz, UCB, Ferris, Fresenius-Kabi; M. Matucci-Cerinic, Biogen, Eli Lilly, Chemomab, Sandoz, Merck/MSD, Pfizer, Behring, Janssen; E. Chamizo Carmona, AbbVie, Amgen, Biogen, Bristol-Myers Squibb(BMS), Celgene, Eli Lilly, Fresenius-Kabi, Galapagos, Janssen, MSD, Novartis, Pfizer, UCB; J. Addison, Biogen.

To cite this abstract in AMA style:

Müller-Ladner U, Gaffney K, Jadon D, Matucci-Cerinic M, Chamizo Carmona E, Addison J. A 48-week Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/a-48-week-analysis-of-a-pan-eu-real-world-study-of-sb5-biosimilar-following-transition-from-reference-adalimumab-in-patients-with-rheumatoid-arthritis-axial-spondyloarthritis-or-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-48-week-analysis-of-a-pan-eu-real-world-study-of-sb5-biosimilar-following-transition-from-reference-adalimumab-in-patients-with-rheumatoid-arthritis-axial-spondyloarthritis-or-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology